| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGb4 |
| Uniprot No | P16144 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-710aa |
| 氨基酸序列 | NRCKKAPVKSCTECVRVDKDCAYCTDEMFRDRRCNTQAELLAAGCQRESI VVMESSFQITEETQIDTTLRRSQMSPQGLRVRLRPGEERHFELEVFEPLE SPVDLYILMDFSNSMSDDLDNLKKMGQNLARVLSQLTSDYTIGFGKFVDK VSVPQTDMRPEKLKEPWPNSDPPFSFKNVISLTEDVDEFRNKLQGERISG NLDAPEGGFDAILQTAVCTRDIGWRPDSTHLLVFSTESAFHYEADGANVL AGIMSRNDERCHLDTTGTYTQYRTQDYPSVPTLVRLLAKHNIIPIFAVTN YSYSYYEKLHTYFPVSSLGVLQEDSSNIVELLEEAFNRIRSNLDIRALDS PRGLRTEVTSKMFQKTRTGSFHIRRGEVGIYQVQLRALEHVDGTHVCQLP EDQKGNIHLKPSFSDGLKMDAGIICDVCTCELQKEVRSARCSFNGDFVCG QCVCSEGWSGQTCNCSTGSLSDIQPCLREGEDKPCSGRGECQCGHCVCYG EGRYEGQFCEYDNFQCPRTSGFLCNDRGRCSMGQCVCEPGWTGPSCDCPL SNATCIDSNGGICNGRGHCECGRCHCHQQSLYTDTICEINYSAIHPGLCE DLRSCVQCQAWGTGEKKGRTCEECNFKVKMVDELKRAEEVVVRCSFRDED DDCTYSYTMEGDGAPGPNSTVLVHKKKDCPPGSLEHHHHHH |
| 预测分子量 | 78 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITGb4重组蛋白的3篇参考文献示例，包含文献名称、作者及简要摘要内容：
1. **文献名称**：*"Integrin β4 signaling promotes tumor angiogenesis and metastasis in murine models"*
**作者**：Mercurio AM, et al.
**摘要**：该研究探讨了重组表达的ITGb4整合素在肿瘤血管生成中的作用，发现其通过激活下游信号通路促进内皮细胞迁移和肿瘤转移，为癌症治疗提供了潜在靶点。
2. **文献名称**：*"Functional characterization of recombinant integrin β4 domains in epithelial cell adhesion"*
**作者**：Santoro SA, et al.
**摘要**：通过基因工程技术表达重组ITGb4蛋白片段，研究发现其胞外结构域对上皮细胞基底膜粘附至关重要，并揭示了其与层黏连蛋白相互作用的分子机制。
3. **文献名称**：*"Recombinant β4 integrin cytoplasmic domain inhibits proliferation and induces apoptosis in breast cancer cells"*
**作者**：Nicolás FJ, et al.
**摘要**：该文献报道了重组ITGb4胞内结构域蛋白的制备及其功能研究，证明其通过干扰生长因子信号传导抑制乳腺癌细胞增殖，并诱导程序性细胞死亡。
**备注**：以上为基于领域知识的示例文献，实际引用时建议通过PubMed或Google Scholar检索最新文章，并使用关键词“recombinant ITGB4”或“integrin beta 4 recombinant protein”获取准确信息。
**Background of Recombinant ITGb4 Protein**
Integrin beta-4 (ITGb4), a subunit of the α6β4 integrin heterodimer, is a transmembrane receptor critical for mediating cell-matrix adhesion and signaling. Unlike other integrin β-subunits, ITGb4 possesses an unusually large cytoplasmic domain containing multiple phosphorylation sites and binding motifs, enabling interactions with signaling adaptors like plectin and cytoskeletal components. This unique structure allows α6β4 integrin to form stable hemidesmosomes, anchoring epithelial cells to the basement membrane, thereby maintaining tissue integrity.
ITGb4 is highly expressed in epithelial tissues, particularly in skin, lung, and gastrointestinal tract. Dysregulation of ITGb4 is implicated in pathologies such as cancer metastasis, blistering skin disorders (e.g., epidermolysis bullosa), and impaired wound healing. In cancer, ITGb4 promotes tumor progression by enhancing cell survival, migration, and invasion through crosstalk with oncogenic signaling pathways (e.g., PI3K/AKT, Ras-MAPK). Conversely, loss-of-function mutations in ITGb4 lead to compromised epithelial adhesion, contributing to genetic disorders.
Recombinant ITGb4 protein is engineered to study its structural and functional roles *in vitro* or *in vivo*. Produced via mammalian or insect expression systems, it retains post-translational modifications critical for ligand binding (e.g., laminins) and signaling activity. Applications include elucidating adhesion mechanisms, screening therapeutic inhibitors, and developing disease models. Its soluble form is also explored for regenerative therapies targeting epithelial damage. Research on recombinant ITGb4 continues to advance understanding of cell adhesion biology and its translational potential in oncology and rare diseases.
×
